Trial Profile
A Study Comparing Persistence Rates and Time to Discontinuation between Rivaroxaban Therapy and Other Oral AntiCcoagulants (OACs)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jul 2017
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Apixaban; Dabigatran etexilate; Warfarin
- Indications Thromboembolism; Thrombosis
- Focus Adverse reactions; Therapeutic Use
- 13 Jul 2017 New trial record